Oslo - Delayed Quote NOK

Arctic Bioscience AS (ABS.OL)

Compare
3.2600
-0.0200
(-0.61%)
As of 1:08:23 PM GMT+1. Market Open.
Currency in NOK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
33,750.0170
33,750.0170
34,271.9360
21,515.0340
20,496.9690
Cost of Revenue
23,976.4230
23,976.4230
22,625.5790
16,356.1510
15,181.9970
Gross Profit
9,773.5940
9,773.5940
11,646.3570
5,158.8830
5,314.9720
Operating Expense
58,359.7580
58,359.7580
49,035.4820
45,736.4990
26,989.6960
Operating Income
-48,586.1640
-48,586.1640
-37,389.1250
-40,577.6160
-21,674.7240
Net Non Operating Interest Income Expense
3,071.4960
3,071.4960
3,364.7610
-2,002.0690
-915.9360
Pretax Income
-45,514.6670
-45,514.6670
-34,024.3640
-42,579.6840
-22,590.6590
Net Income Common Stockholders
-45,514.6670
-45,514.6670
-34,024.3640
-42,579.6840
-22,590.6590
Diluted NI Available to Com Stockholders
-45,514.6670
-45,514.6670
-34,024.3640
-42,579.6840
-22,590.6590
Basic EPS
-1.79
-1.79
-1.39
-1.75
-0.93
Diluted EPS
-1.79
-1.79
-1.39
-1.75
-0.93
Basic Average Shares
25,427.1880
25,427.1880
24,477.9600
24,331.2480
24,299.5390
Diluted Average Shares
25,427.1880
25,427.1880
24,477.9600
24,331.2480
24,299.5390
Total Operating Income as Reported
-48,586.1640
-48,586.1640
-37,389.1250
-40,577.6160
-21,674.7240
Total Expenses
82,336.1810
82,336.1810
71,661.0610
62,092.6500
42,171.6930
Net Income from Continuing & Discontinued Operation
-45,514.6670
-45,514.6670
-34,024.3640
-42,579.6840
-22,590.6590
Normalized Income
-45,514.6670
-45,514.6670
-34,024.3640
-42,579.6840
-22,590.6590
Interest Income
3,735.8850
3,735.8850
1,892.8650
118.5820
18.3860
Interest Expense
992.6230
992.6230
1.2500
342.0320
509.6300
Net Interest Income
3,071.4960
3,071.4960
3,364.7610
-2,002.0690
-915.9360
EBIT
-44,522.0440
-44,522.0440
-34,023.1140
-42,237.6520
-22,081.0290
EBITDA
-39,139.5590
-39,139.5590
-30,292.4420
-39,719.7130
-20,889.0770
Reconciled Cost of Revenue
23,976.4230
23,976.4230
22,625.5790
16,356.1510
15,181.9970
Reconciled Depreciation
5,382.4850
5,382.4850
3,730.6720
2,517.9390
1,191.9520
Net Income from Continuing Operation Net Minority Interest
-45,514.6670
-45,514.6670
-34,024.3640
-42,579.6840
-22,590.6590
Total Unusual Items Excluding Goodwill
--
--
--
--
-967.5350
Total Unusual Items
--
--
--
--
-967.5350
Normalized EBITDA
-39,139.5590
-39,139.5590
-30,292.4420
-39,719.7130
-20,889.0770
12/31/2020 - 2/24/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ELIC.ST Elicera Therapeutics AB (publ)
3.3500
+0.90%
 
NXTCL.ST NextCell Pharma AB
2.8600
-0.69%
 
ACE.ST Ascelia Pharma AB (publ)
2.8900
+1.05%
 
GANX Gain Therapeutics, Inc.
2.2000
+5.26%
 
ALZN Alzamend Neuro, Inc.
1.1500
+2.68%
 
APRE Aprea Therapeutics, Inc.
3.8000
+2.43%
 
ADPT Adaptive Biotechnologies Corporation
7.86
+1.95%
 
MIST Milestone Pharmaceuticals Inc.
2.0200
+1.00%
 
UBX Unity Biotechnology, Inc.
2.1400
-4.46%
 
ELEV Elevation Oncology, Inc.
0.6666
+7.78%